Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Neelapu on Interim Results of the Phase II ZUMA-1 Study in DLBCL

Sattva S. Neelapu, MD
Published: Wednesday, Dec 28, 2016



Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma (DLBCL).

ZUMA-1 is a pivotal multicenter trial of KTE-C19, the tested anti-CD19 chimeric antigen receptor T-cell therapy, in patients with refractory DLBCL. According to Neelapu, KTE-C19 is essentially a genetically engineered T-cell product that is trained to recognize CD19 that is expressed on the tumor cells.

At the 2016 ASH Annual Meeting, Neelapu presented the prespecified interim analysis of ZUMA-1, which included patients who had at least 3 months of follow-up after KTE-C19 infusion. The 51 patients with DLBCL in the study were found to yield significant clinical benefit from treatment with KTE-C19. The overall response rate was 76%, and the complete response rate was 47%, says Neelapu.


Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses interim results of the phase II ZUMA-1 study in patients with diffuse large B-cell lymphoma (DLBCL).

ZUMA-1 is a pivotal multicenter trial of KTE-C19, the tested anti-CD19 chimeric antigen receptor T-cell therapy, in patients with refractory DLBCL. According to Neelapu, KTE-C19 is essentially a genetically engineered T-cell product that is trained to recognize CD19 that is expressed on the tumor cells.

At the 2016 ASH Annual Meeting, Neelapu presented the prespecified interim analysis of ZUMA-1, which included patients who had at least 3 months of follow-up after KTE-C19 infusion. The 51 patients with DLBCL in the study were found to yield significant clinical benefit from treatment with KTE-C19. The overall response rate was 76%, and the complete response rate was 47%, says Neelapu.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x